The CSSA is honored to announce that Dr. Christian Pagnoux, Dr. Bruce Bochner and Dr. Gerald Gleich have accepted our invitations to serve on the CSSA Medical Advisory Board.
Dr. Christian Pagnoux, a renown researcher at Hopital Cochin in Paris, has a long standing interest in treating and researching Churg Strauss Syndrome. His research interest in Churg Strauss Syndrome is well documented with his name as author or co-author on over 25 research articles relating to CSS on PubMed. His two most recent articles are: Churg-Strauss syndrome: evolving concepts. Pagnoux C. Marmursztejn J, Vignaux O, Cohen P, Guilpain P, Pagnoux C, Gouya H, Mouthon L, Legmann P, Duboc D, Guillevin L. Dr. Pagnoux is Vice President of the prestigious French
Vasculitis Study Group. The French Vascultis
Study Group has been in the forefront of advancing an understanding
of CSS. The FVSG's interest and commitment to CSS research has been
commendable. Some of the latest research studies the include
the following topics: the prevalence of ANCA in CSS, the different
course the disease may take depending on whether the patient is
ANCA negative or positive, epidemiological studies, and cardiac
imaging and involvement in CSS.The CSSA is planning a feature article
about the French Vasculitis Study Group to recognize and celebrate
their dedication to CSS research in an upcoming website update.
Many of the current CSS Medical Advisory Board members are experts
in vasculitis. The two most recent members of our Board, Dr. Bruce
Bochner and Dr. Gerald Gleich, study the role the eosinophil plays
in allergy, asthma and immune responses. This research is yielding
important information relevant to hypereosnophilic diseases, including
CSS. Dr. Bruce Bochner is a Professor of Medicine and Director of the Division of Allergy and Clinical Immunology at Johns Hopkins Asthma and Allergy Center in Baltimore, MD. His research interest is in the role eosinophils play in disease processes, including CSS. He is a Fellow of the American Academy of Allergy Asthma and Immunology and the American College of Physicians, and a member of the American College of Allergy, Asthma & Immunology, the Association of American Physicians, American Association of Immunologists, the American Society for Clinical Investigation, and the Collegium Internationale Allergologicum. He is the author of more than 180 peer-reviewed publications, reviews, and book chapters. He lectures extensively on a variety of topics, including both clinical and experimental aspects of allergic diseases. Dr. Bochner was a member of the Hypereosinophila Syndromes Working group, a workshop was funded by Office of Rare Diseases Research of the National Institutes of Health, GlaxoSmithKline (GSK), and the American Partnership for Eosinophilic Disorders.
Bochner Lab 2008-2009 (left to right: Hui Mao, Bruce Bochner, Chang-Shin Park, Ho Jeong Na). Some of Dr. Bochners recent research articles include: What targeting eosinophils has taught us about their role in diseases. Bochner BS, Gleich GJ. Eosinophil survival and apoptosis in health and disease. Park YM, Bochner BS.
Dr Gleich was also a member of the Hypereosinophilic Syndromes Working Group: "A multidisciplinary group of 37 clinicians and scientists participated in a workshop held in May 2005 in Bern, Switzerland to discuss current and future approaches to therapy for 3 eosinophil-mediated disorders: hypereosinophilic syndrome, Churg-Strauss syndrome, and eosinophil-associated gastrointestinal disease. The goal of the workshop was to summarize available data regarding treatment of these disorders to identify the most promising therapies and approaches for further study. There was consensus among all of the participants that the identification of markers of disease progression to assess treatment responses is a research priority for all 3 disorders. Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multi-center trials to assess all treatment modalities, was emphasized." Dr. Gleich's recent research includes: Eosinophil ribonucleases and their cutaneous lesion-forming activity. Plager DA, Davis MD, Andrews AG, Coenen MJ, George TJ, Gleich GJ, Leiferman KM. Anti-interleukin-5 therapy and severe asthma. Gleich GJ. Dr. Gleich is dedicated to working with and supporting patient groups and serves both on the Board of Directors and Medical Advisory Panel of the American Partnership for Eosinophilic Disorders (APFED). |
Dr.
Gerald Gleich is Professor of Dermatology, Medicine
and Pediatrics at the University of Utah. Dr. Gleich has
had a life-long professional commitment to understanding the eosinophil
with a focus on its distinctive granules. He and his colleagues
have isolated, characterized, identified the cDNAs and the genes
and established assays for measurement and localization of all of
the principal granule proteins. These efforts lead to the
recognition that eosinophil degranulation with release of cytotoxic
and cytostimulatory cationic ptoteins into tissues is characteristic
of eosinophil-associated diseases and to recognition of several
novel syndromes. As a consequence of these efforts, Dr. Gleich
is an internationally recognized authority on diseases associated
with eosinophils and regularly consults on their diagnosis and treatment.
|
